Soluble Receptor of Advanced Glycated Endproducts Is Associated With Plaque Vulnerability in Patients With Acute Myocardial Infarction

Park, Hun‐Jun; Baek, Ju-Yeol; Shin, Woo Seung; Kim, Dong‐Bin; Jang, Sung Won; Shin, Dong Il; Koh, Yoon Seok; Seo, Suk Min; Uhm, Jae Sun; Kim, Tae Hoon; Kim, Chan Joon; Kim, Pum Joon; Chang, Kiyuk; Chung, Wook Sung; Seung, Ki‐Bae; Lee, Jong Min

doi:10.1253/circj.cj-10-1248

Cited by 31 publications

(29 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This basic research suggests that atherosclerotic plaque rupture, in which MMP-9 is expressed, may raise systemic MMP-9 levels. Previous clinical studies also clarified that blood MMP-9 levels are elevated in patients with ACS [21,22,23], especially during the early phase (within 4 h from ACS onset) [24]. In addition, another study demonstrated that MMP-9 levels in coronary circulation were elevated in patients with ACS by the use of blood samples obtained from the aorta and great cardiac vein [25].…”

Section: Discussionmentioning

confidence: 99%

Matrix Metalloproteinase-9 as a Marker for Plaque Rupture and a Predictor of Adverse Clinical Outcome in Patients with Acute Coronary Syndrome: An Optical Coherence Tomography Study

Kobayashi¹,

Takano²,

Hata³

et al. 2016

Cardiology

View full text Add to dashboard Cite

Objectives: The present study sought to clarify the relationship between matrix metalloproteinase-9 (MMP-9) levels and plaque morphology demonstrated by optical coherence tomography (OCT), and to examine their prognostic impacts in patients with acute coronary syndrome (ACS). Methods: MMP-9 levels were measured for patients with ACS (n = 249). Among 249 patients, 120 with evaluable OCT images were categorized into patients with ruptured plaques (n = 65) and those with nonruptured plaques (n = 55) on the basis of culprit lesion plaque morphology demonstrated by OCT. Results: MMP-9 levels on admission were significantly higher in the rupture group than in the nonrupture group (p = 0.029). Although creatine kinase-MB (CK-MB) on admission was comparable between the groups, peak CK-MB was higher in the rupture group than in the nonrupture group (p < 0.001). By receiver operating characteristic curve analysis, the optimal cut-off value of MMP-9 to detect ruptured plaques was 65.5 ng/ml (p = 0.029). There was a nonstatistically significant trend toward increased cardiac death at 2 years (5.9 vs. 1.0%, p = 0.059) in patients with high MMP-9 (≥65.5 ng/ml) compared to those with low MMP-9 (<65.5 ng/ml). Conclusions: MMP-9 can differentiate ACS with ruptured plaques from nonruptured plaques, and MMP-9 may be a valuable predictor of long-term cardiac mortality in patients with ACS reflecting plaque rupture.

show abstract

Section: Discussionmentioning

confidence: 99%

Matrix Metalloproteinase-9 as a Marker for Plaque Rupture and a Predictor of Adverse Clinical Outcome in Patients with Acute Coronary Syndrome: An Optical Coherence Tomography Study

Kobayashi¹,

Takano²,

Hata³

et al. 2016

Cardiology

View full text Add to dashboard Cite

show abstract

“…Interestingly, expression of soluble RAGE has been reported to be elevated in patients with acute myocardial infarction. 24 The S100A8/9 heterodimer, another S100A protein, has been associated with an increased risk of cardiovascular events in a case-control study using patients enrolled in the PROVEIT-TIMI22 trial. 25 In the present study, S100A12 was a significant predictor of MACE in patients with stable CAD.…”

Section: Discussionmentioning

confidence: 99%

S100A12 as a Marker to Predict Cardiovascular Events in Patients With Chronic Coronary Artery Disease

Saito

Hojo

Ogoyama

et al. 2012

Circ J

View full text Add to dashboard Cite

“…The time interval (median, 25 th and 75 th percentiles) from symptom onset to arrival at the ER (point 1), the start of CAG (point 2), the termination of PCI (point 3), and hospital discharge (point 7) was 82 min, 64 min, and 165 min, 124 min, 100 min and 187 min, 203 min, 167 min, and 247 min and 15 days, 12 days and 19 days, respectively. Time from onset to discharge from hospital (days) 15 (12)(13)(14)(15)(16)(17)(18)(19) Data given as n (%), mean ± SD or median (25 th -75 th percentile). ER, emergency room; CAG, coronary angiography; PCI, percutaneous coronary intervention.…”

Section: Comparison Of Time-dependent Changes In Mmp-9 With Hs-tntmentioning

confidence: 99%

“…11,13,14 Levels of MMP-9 especially those in coronary circulation, are significantly higher in ACS than in control subjects. [15][16][17][18] Previous studies, which evaluated plaque rupture using intravascular ultrasound and virtual histology intravascular ultrasound, indicated that MMP-9 levels were significantly higher in ACS patients with plaque rupture than those without. 19, 20 Thus, previous studies have provided evidence that MMP-9 reflects atherosclerotic plaque rupture or vulnerability, but the diagnostic value or time-dependent changes of MMP-9 at the earliest stage of ACS have not been compared with other biomarkers.…”

mentioning

confidence: 99%

Matrix Metalloproteinase-9 for the Earliest Stage Acute Coronary Syndrome - Comparison With High-Sensitivity Troponin T -

Kobayashi

Hata

Kume

et al. 2011

Circ J

View full text Add to dashboard Cite

Background: Matrix metalloproteinase-9 (MMP-9) is regarded as a biomarker of plaque rupture or vulnerability and is elevated in patients with acute coronary syndrome (ACS). The aim of the present study was to evaluate the diagnostic value of MMP-9 for early ACS (≤4 h of onset) and late ACS (>4 h after onset), compared with high-sensitivity troponin T (hs-TnT). Methods and Results:MMP-9 and hs-TnT were measured in 200 patients with ST elevation ACS (STEACS; 115 early STEACS and 85 late STEACS patients), and 66 patients with non-ST elevation ACS (NSTEACS; 25 early NSTEACS and 41 late NSTEACS patients). Forty patients with stable angina pectoris (SAP) were enrolled as a control group. MMP-9 levels were significantly higher in patients with early STEACS (P<0.001), early NSTEACS (P<0.001), late STEACS (P<0.001) and late NSTEACS (P=0.025) than SAP. MMP-9 levels were significantly higher in patients with early STEACS (P=0.017) and early NSTEACS (P=0.034) than late STEACS and late NSTEACS, respectively. Levels of hs-TnT were significantly lower in patients with early STEACS (P<0.001) and early NSTEACS (P=0.007) than late STEACS and late NSTEACS, respectively. On receiver operating characteristic curve analysis, area under the curve of early STEACS, early NSTEACS, late STEACS and late NSTEACS was 0.880, 0.782, 0.790 and 0.648 for MMP-9, and 0.707, 0.725, 0.993 and 0.920 for hs-TnT, respectively.Conclusions: MMP-9 levels were elevated earlier than hs-TnT and had a higher diagnostic value for early ACS, but not for late ACS, reflecting plaque rupture or vulnerability. (Circ J 2011; 75: 2853 - 2861

show abstract

Soluble Receptor of Advanced Glycated Endproducts Is Associated With Plaque Vulnerability in Patients With Acute Myocardial Infarction

Cited by 31 publications

References 32 publications

Matrix Metalloproteinase-9 as a Marker for Plaque Rupture and a Predictor of Adverse Clinical Outcome in Patients with Acute Coronary Syndrome: An Optical Coherence Tomography Study

Matrix Metalloproteinase-9 as a Marker for Plaque Rupture and a Predictor of Adverse Clinical Outcome in Patients with Acute Coronary Syndrome: An Optical Coherence Tomography Study

S100A12 as a Marker to Predict Cardiovascular Events in Patients With Chronic Coronary Artery Disease

Matrix Metalloproteinase-9 for the Earliest Stage Acute Coronary Syndrome - Comparison With High-Sensitivity Troponin T -

Contact Info

Product

Resources

About